Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 293,291
  • Shares Outstanding, K 143,770
  • Annual Sales, $ 7,530 K
  • Annual Income, $ -60,410 K
  • 36-Month Beta 1.88
  • Price/Sales 39.16
  • Price/Cash Flow 0.00
  • Price/Book 13.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.86 +4.84%
on 06/30/17
2.21 -11.76%
on 07/17/17
-0.05 (-2.50%)
since 06/27/17
3-Month
1.60 +21.88%
on 05/22/17
2.58 -24.42%
on 04/28/17
-0.57 (-22.62%)
since 04/27/17
52-Week
1.60 +21.88%
on 05/22/17
3.72 -47.58%
on 11/15/16
+0.19 (+10.80%)
since 07/27/16

Most Recent Stories

More News
Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will...

CRIS : 1.95 (-4.41%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that...

CRIS : 1.95 (-4.41%)
UPDATE - Curis to Present at the Jefferies Healthcare Conference

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Ali Fattaey,...

CRIS : 1.95 (-4.41%)
Curis to Present at the Jefferies Healthcare Conference

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that Ali Fattaey,...

CRIS : 1.95 (-4.41%)
Research Reports Initiation on Biotech Stocks -- Corcept Therapeutics, Curis, OvaScience, and Vanda Pharma

On Friday, May 26, 2017, US markets saw a mixed session as 4 sectors closed in green, 2 sectors finished in red, and 3 sectors ended flat for the day. Major US indices were also mixed at the close of last...

CORT : 12.10 (-0.82%)
CRIS : 1.95 (-4.41%)
OVAS : 1.48 (-3.27%)
VNDA : 15.70 (-1.88%)
Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation...

CRIS : 1.95 (-4.41%)
Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will...

CRIS : 1.95 (-4.41%)
Research Reports Initiation on Biotech Stocks -- Alnylam Pharma, INSYS Therapeutics, Curis, and GenVec

For today, Stock-Callers.com features the following Biotech stocks: Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), INSYS Therapeutics Inc. (NASDAQ: INSY), Curis Inc. (NASDAQ: CRIS), and GenVec Inc. (NASDAQ:...

GNVC : 7.19 (-0.28%)
CRIS : 1.95 (-4.41%)
ALNY : 79.59 (-2.43%)
INSY : 11.54 (-4.07%)
Curis Reports Fourth Quarter and Year-End 2016 Financial Results

-- Company Announces $45 million Debt Transaction with HealthCare Royalty Partners Secured with Future Erivedge Royalty --

CRIS : 1.95 (-4.41%)
Curis to Release Fourth Quarter and Year End 2016 Financial Results and Hold Conference Call on March 9, 2017

Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that...

CRIS : 1.95 (-4.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Support & Resistance

2nd Resistance Point 2.14
1st Resistance Point 2.09
Last Price 1.95
1st Support Level 2.00
2nd Support Level 1.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.